Wittycell Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Merger of Eq.
  • Financing Rounds
  • 3

Wittycell General Information

Description

Developer of products for therapeutic and prophylactic vaccines based on the company's proprietary technology. The Company develops novel lipid adjuvant products developed in collaboration with three world renowned academic institutions, the Scripps Research Institute (California), the University of Chicago and the Brigham Young University (Utah).

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 8, Bis rue Gabriel Voisin
  • 51100 Reims
  • France
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Wittycell Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Wittycell‘s full profile, request access.

Request a free trial

Wittycell Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial